Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala

INTRODUCTION: In 2011 Uganda recommended boosted atazanavir (ATV/r) as the preferred PI for second line due to once daily dosing, replacing aluvia (LPV/r) [1, 2]. The evidence was based on the BMS O45 trial, of LPV/r vs ATV/r was performed in a high-income setting, on patients with prior PI use and...

Descripción completa

Detalles Bibliográficos
Autores principales: Laker, Eva, Mambule, Ivan, Nalwanga, Damalie, Musaazi, Joseph, Kiragga, Agnes, Parkes-Ratanshi, Rosalind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P260
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225351/
https://www.ncbi.nlm.nih.gov/pubmed/25397536
http://dx.doi.org/10.7448/IAS.17.4.19792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225351/
https://www.ncbi.nlm.nih.gov/pubmed/25397536
http://dx.doi.org/10.7448/IAS.17.4.19792

Ejemplares similares